Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 5 | 2016 | 354 | 0.390 |
Why?
|
| Health Personnel | 3 | 2014 | 241 | 0.260 |
Why?
|
| Interferon-gamma Release Tests | 2 | 2014 | 8 | 0.220 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2002 | 7 | 0.210 |
Why?
|
| Oxazolidinones | 1 | 2002 | 8 | 0.210 |
Why?
|
| Acetamides | 1 | 2002 | 20 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2016 | 255 | 0.210 |
Why?
|
| Tuberculosis | 2 | 2014 | 141 | 0.200 |
Why?
|
| Depressive Disorder | 2 | 2016 | 339 | 0.200 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 97 | 0.190 |
Why?
|
| Depression | 3 | 2016 | 564 | 0.180 |
Why?
|
| Hot Temperature | 5 | 1990 | 208 | 0.150 |
Why?
|
| Primary Health Care | 2 | 2011 | 353 | 0.150 |
Why?
|
| Cooperative Behavior | 3 | 2015 | 223 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 133 | 0.130 |
Why?
|
| Neoplasms, Experimental | 3 | 1991 | 114 | 0.130 |
Why?
|
| Hydroxyquinolines | 2 | 1991 | 4 | 0.120 |
Why?
|
| Oxyquinoline | 2 | 1991 | 8 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2015 | 222 | 0.120 |
Why?
|
| Interferon-gamma | 2 | 2012 | 174 | 0.110 |
Why?
|
| Water Microbiology | 2 | 2002 | 28 | 0.100 |
Why?
|
| Mass Screening | 2 | 2014 | 351 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2014 | 280 | 0.100 |
Why?
|
| Latent Tuberculosis | 1 | 2011 | 10 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 42 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 245 | 0.090 |
Why?
|
| Cell Survival | 4 | 1985 | 598 | 0.090 |
Why?
|
| Telemedicine | 1 | 2016 | 443 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 176 | 0.090 |
Why?
|
| Mental Health Services | 1 | 2011 | 194 | 0.080 |
Why?
|
| United States | 6 | 2016 | 4838 | 0.080 |
Why?
|
| Middle Aged | 9 | 2015 | 11997 | 0.070 |
Why?
|
| Mannose | 2 | 1984 | 16 | 0.070 |
Why?
|
| Tetracyclines | 1 | 2005 | 7 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2005 | 17 | 0.060 |
Why?
|
| Aspergillus | 2 | 2002 | 52 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 273 | 0.060 |
Why?
|
| Hospitals | 2 | 2002 | 175 | 0.060 |
Why?
|
| Bleomycin | 1 | 1984 | 35 | 0.060 |
Why?
|
| Male | 13 | 2015 | 25093 | 0.060 |
Why?
|
| Humans | 18 | 2016 | 49827 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 279 | 0.050 |
Why?
|
| Doxorubicin | 1 | 1984 | 230 | 0.050 |
Why?
|
| Fungi | 1 | 2002 | 44 | 0.050 |
Why?
|
| Adult | 8 | 2015 | 13160 | 0.050 |
Why?
|
| Cisplatin | 1 | 1984 | 278 | 0.050 |
Why?
|
| Water Pollution | 1 | 2002 | 8 | 0.050 |
Why?
|
| Cefotaxime | 1 | 1981 | 4 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2005 | 269 | 0.050 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1981 | 8 | 0.050 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2001 | 4 | 0.050 |
Why?
|
| Ehrlichiosis | 1 | 2001 | 15 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2005 | 326 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2005 | 743 | 0.050 |
Why?
|
| Mycoses | 1 | 2002 | 158 | 0.050 |
Why?
|
| HIV-1 | 1 | 2001 | 55 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 99 | 0.050 |
Why?
|
| Candidiasis | 1 | 1981 | 114 | 0.050 |
Why?
|
| Time Factors | 4 | 2014 | 2912 | 0.040 |
Why?
|
| Glucuronidase | 2 | 1991 | 46 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5138 | 0.040 |
Why?
|
| Female | 11 | 2015 | 26329 | 0.040 |
Why?
|
| Ehrlichia | 2 | 2001 | 6 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2016 | 258 | 0.030 |
Why?
|
| Cell Line | 4 | 1990 | 1002 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 273 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 1991 | 81 | 0.030 |
Why?
|
| Cricetinae | 4 | 1990 | 192 | 0.030 |
Why?
|
| Rickettsiaceae Infections | 1 | 1992 | 1 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2012 | 9 | 0.030 |
Why?
|
| Animals | 8 | 1991 | 13150 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 116 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1991 | 85 | 0.020 |
Why?
|
| Quinolines | 1 | 1991 | 39 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 904 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2012 | 151 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1991 | 174 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1991 | 164 | 0.020 |
Why?
|
| Nurse Administrators | 1 | 2011 | 12 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2014 | 6117 | 0.020 |
Why?
|
| Aged | 4 | 2015 | 9272 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 96 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 374 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1188 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 1990 | 7 | 0.020 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 1990 | 6 | 0.020 |
Why?
|
| Sodium Compounds | 1 | 1990 | 11 | 0.020 |
Why?
|
| Arsenites | 1 | 1990 | 13 | 0.020 |
Why?
|
| Kinetics | 3 | 1990 | 626 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2011 | 126 | 0.020 |
Why?
|
| Psychiatry | 1 | 2011 | 105 | 0.020 |
Why?
|
| Mice | 3 | 1991 | 5720 | 0.020 |
Why?
|
| Cefamandole | 1 | 1989 | 1 | 0.020 |
Why?
|
| Pharmacists | 1 | 2011 | 144 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2011 | 325 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 548 | 0.020 |
Why?
|
| Health Status | 1 | 2011 | 298 | 0.020 |
Why?
|
| Galactose | 2 | 1985 | 28 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 942 | 0.020 |
Why?
|
| Cricetulus | 2 | 1984 | 97 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1989 | 214 | 0.020 |
Why?
|
| Glucose | 2 | 1985 | 340 | 0.020 |
Why?
|
| Carbohydrates | 1 | 1985 | 40 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2179 | 0.020 |
Why?
|
| Quality of Life | 1 | 2011 | 833 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 2 | 1982 | 271 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 378 | 0.010 |
Why?
|
| Aging | 1 | 1989 | 688 | 0.010 |
Why?
|
| Chlorine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Air Microbiology | 1 | 2002 | 12 | 0.010 |
Why?
|
| Water Supply | 1 | 2002 | 22 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 59 | 0.010 |
Why?
|
| Brain Abscess | 1 | 1982 | 12 | 0.010 |
Why?
|
| Phagocytes | 1 | 1982 | 12 | 0.010 |
Why?
|
| Nocardia Infections | 1 | 1982 | 5 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 116 | 0.010 |
Why?
|
| Neisseria gonorrhoeae | 1 | 1981 | 4 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2002 | 120 | 0.010 |
Why?
|
| Candida albicans | 1 | 1981 | 31 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 3125 | 0.010 |
Why?
|
| Air Pollution | 1 | 2002 | 43 | 0.010 |
Why?
|
| Cross Infection | 1 | 2002 | 95 | 0.010 |
Why?
|
| Aspergillosis | 1 | 2002 | 125 | 0.010 |
Why?
|
| Leucomycins | 1 | 1979 | 1 | 0.010 |
Why?
|
| Penicillin G | 1 | 1979 | 4 | 0.010 |
Why?
|
| Meningitis, Pneumococcal | 1 | 1979 | 7 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1988 | 1172 | 0.010 |
Why?
|
| Bacteria | 1 | 1981 | 223 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1990 | 465 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1981 | 283 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 2344 | 0.010 |
Why?
|
| Ovary | 2 | 1985 | 104 | 0.010 |
Why?
|
| Infant | 1 | 1981 | 3551 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1981 | 3853 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 1992 | 41 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1992 | 185 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 455 | 0.010 |
Why?
|
| Diamide | 1 | 1990 | 2 | 0.010 |
Why?
|
| Sialyltransferases | 1 | 1990 | 3 | 0.010 |
Why?
|
| Fucosyltransferases | 1 | 1990 | 5 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1990 | 37 | 0.010 |
Why?
|
| Adolescent | 1 | 1981 | 6340 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1990 | 22 | 0.010 |
Why?
|
| Arsenic | 1 | 1990 | 24 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 1990 | 99 | 0.010 |
Why?
|
| Cefonicid | 1 | 1989 | 1 | 0.010 |
Why?
|
| Child | 1 | 1981 | 6824 | 0.010 |
Why?
|
| Creatinine | 1 | 1989 | 140 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1988 | 118 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1988 | 636 | 0.000 |
Why?
|
| Hexoses | 1 | 1985 | 5 | 0.000 |
Why?
|
| Deoxy Sugars | 1 | 1985 | 4 | 0.000 |
Why?
|
| Lactose | 1 | 1985 | 9 | 0.000 |
Why?
|
| Butyric Acid | 1 | 1985 | 10 | 0.000 |
Why?
|
| Carbohydrate Metabolism | 1 | 1985 | 26 | 0.000 |
Why?
|
| Butyrates | 1 | 1985 | 30 | 0.000 |
Why?
|
| Galactitol | 1 | 1984 | 3 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1990 | 1169 | 0.000 |
Why?
|
| Streptococcus pneumoniae | 1 | 1979 | 22 | 0.000 |
Why?
|
| Rabbits | 1 | 1979 | 370 | 0.000 |
Why?
|